REFERENCE FILE
Liraglutide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- Activates the GLP-1 receptor.
- Evidence
- Randomized trials.
- Limitations
- Check other products separately.
- Safety
- The label warns about severe gastrointestinal reactions.
- Formulation and route
- Subcutaneous injection.
- Approval scope
- Saxenda: weight management for eligible patients.
A SECOND LOOK
A question to carry into the reading
For a report mentioning liraglutide, build a short timeline of the questions being asked. Locate any dated plan or registration, then place the reported analyses beside it. Separate questions you can verify were specified beforehand from questions introduced later; keep uncertain timing in its own column. For a later question, write what prompted it only if the report explains that choice. This exercise does not require dismissing an interesting observation. It asks you to distinguish discovering a possible pattern from testing a question that was already defined, and to identify what a subsequent investigation would need to specify in advance.
Questions to keep beside the page
- Where can I find a dated record of the original questions?
- Which reported analyses can I match to that earlier record?
- What would a later investigation need to specify before testing the new question?
Sources for this file
- SAXENDANLM · Checked
FROM THE REFERENCE DESK